CORRECTING and REPLACING -- Enzymotec Ltd. Reports Fourth Quarter and Full Year 2015 Results
Fourth Quarter Non-GAAP Net Income* of $0.07 per Diluted Share Inclusive of $0.05 for Accelerated Growth Initiative Spend VAYA Pharma Generates Record Net Revenues of $2.3 Million in the Quarter and $8.5 Million in the Full Year MIGDAL HA'EMEQ, Israel, …